Scaling CAR T Beyond Academic Medical Centers: Cell Therapy Needs an Ecosystem
CAR T access will depend not on replicating academic cell therapy infrastructure at every community hospital, but on connecting specialized capabilities across existing healthcare networks.
CAR T therapy has transformed treatment for several blood cancers, but only 2 of every 10 patients who could benefit from these therapies can access them. Less than 15% of CAR T is delivered outside of academic medical centers, even though most cancer care overall happens in community oncology practices. The access gap is worse still when broken down by race and proximity to appropriate facilities.
As CAR T indications broaden into areas like autoimmune disease, academic centers alone are unlikely to have the capacity to meet demand. Scaling that expertise will require extending capability to the settings where patients already receive care.
Most community hospitals aren’t starting from nothing. They already belong to health systems, physician networks, and specialty relationships that carry much of what CAR T requires—inpatient care, oncology support, and existing blood center relationships. Hospitals may be able to participate in delivering CAR T by filling in whatever specific piece its network doesn’t already cover—collection, storage, specialist consultation, laboratory support, or quality expertise.
The evolution of specialized care
While academic medical centers will always play a role in advancing cell therapies, broader access to cell therapy depends on community hospitals. These already operate a model of outsourcing specialized services that would be difficult to maintain independently, such as radiology, pathology, and other capabilities that don’t need to be physically duplicated at every site, whether delivered on-site or remotely. That’s a make-or-buy calculation.
In a parallel model, dialysis care itself has shifted from inpatient to freestanding outpatient facilities to expand access and cut cost. By 2016 those facilities provided 94% of fee-for-service Medicare dialysis treatments. Cell therapy needs both capability bought where it doesn’t make sense to build and care relocated closer to where patients already are.
One key group in that distributed model is blood supplier, a biologics partner fluent in the regulatory terrain cell therapy requires. Beyond blood and transfusion support, many already support tissue services, solid organ transplantation, therapeutic apheresis, and cellular therapy processing laboratories. Community hospitals with an existing blood center relationship should treat it as part of their own extended ecosystem.
Not every hospital needs every capability
Community hospitals preparing to participate in CAR T delivery will likely already have some of the necessary infrastructure or access it through existing relationships. One hospital may have apheresis but lack product storage. Another may have strong oncology and inpatient capabilities or a telehealth relationship with an academic CAR T program attempting to extend treatment to local patients.
That makes a standardized “CAR T hospital” checklist less useful than a network-based assessment of what’s already there.
In practice, current demand concentrates on two points: collection support and infusion support—the first and last mile of the CAR T pathway. Getting the first mile right matters beyond convenience. Disease burden at the time of treatment is a known driver of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) severity. Shortening the delay between diagnosis and collection preserves T-cell fitness before cumulative therapy erodes it, which may improve product quality and response durability, not just access to treatment.
Cytokine release syndrome
CRS is a side effect of immunotherapy that results in widespread inflammation after cytokines are released into the bloodstream. In some cases, CRS can be life-threatening.
Immune effector cell-associated neurotoxicity syndrome
Similar to CRS, ICANS is a side effect of immunotherapy, but the associated inflammation damages the brain and nervous system and can lead to potentially fatal swelling in the brain.
For patients who need extra support during collection, such as point-of-care testing and monitoring, a community hospital doesn’t need its own apheresis program to help. It can provide that support in its outpatient setting while an apheresis partner performs the collection itself.
Cell therapy laboratories already function as the hub in this work, coordinating directly with CAR T vendors on pre-manufacturing testing and cell processing, and holding the finished product for the short window between manufacturing and infusion.
Maintaining specialized expertise
In 2025, the US Food and Drug Administration eased certain site certification rules, but CRS and ICANS still require clinicians who can recognize, grade, and manage them. As specialty groups increasingly deliver CAR T and related therapies in community settings, they’ll likely lean on the hospital the way oncology already leans on hospitalists: for acute in-house support when a patient needs it.
Hospital medicine is built as its own discipline, not borrowed capacity from a busier department. Adverse event management for CAR T needs the same kind of purpose-built home—credentialed, staffed, and available on the hospital’s own schedule—rather than layered onto oncology, nursing, or an academic team’s existing workload. The goal is making sure that expertise is reliably present when a patient needs it.
Ready to go
Many blood suppliers already have the resources in place—either primary to the hospital or a secondary supplier already serving its network. If those resources aren't currently in the region, one of the suppliers may be able to extend its hub-and-spoke model rather than build a new one. The contractual relationship in these cases usually already exists as a master services agreement, and CAR T support can be added as a statement of work rather than negotiated from scratch. What's usually missing is the demand to justify extending the service, something that is particularly valuable for systems spanning multiple states.
Beyond collection and storage, blood centers can bring specialized apheresis nursing, cell therapy laboratory capacity, medical director oversight, and quality and regulatory expertise specific to blood and biologics—along with direct relationships with CAR T vendors that most hospitals don’t have reason to build on their own. Cells travel from distant community hospitals to a central hub for manufacturing coordination, then back out again for infusion, with the cell therapy laboratory managing pre-manufacturing testing, processing, and the final-mile logistics in between.
Preparing for CAR T
Community hospitals can begin by evaluating what they already have. That typically includes existing clinical capabilities, apheresis, patient management systems, toxicity monitoring protocols, and a hospitalist model that can be extended.
Before building new infrastructure, hospitals should audit what their existing network already provides—collection, storage, specialist relationships, and telehealth—and how each partner is currently classified. The gap most systems have is a network they haven’t fully counted.
Table 1. Common CAR T care components and potential partnering network opportunities to fill gaps in community settings.
| CAR T care component | Exists locally? | Potential network extension |
| Inpatient/bedside care | Often | Community hospital |
| Toxicity monitoring | Often | Community hospital, with escalation support |
| CRS/ICANS specialist management | Less common | Academic specialist or telehealth relationship |
| Apheresis/collection | Variable | Hospital program or blood center |
| Product storage | Variable | Cell therapy or blood center laboratory |
| Chain of identity/custody | Less likely | Blood center or quality/regulatory infrastructure |
| Quality/regulatory support | Variable | Network quality team or specialized partner |
| Specialized apheresis nursing | Less common | Blood center or established cellular therapy program |
Collaboration will determine whether CAR T reaches its full potential
The scientific barriers that once defined CAR T are gradually giving way to operational ones as the therapy scales into more patients and, potentially, more diseases. What comes next depends on building the internal capacity a hospital can own, paired with external relationships for the specialized expertise it can’t and shouldn’t try to replicate on its own.
No single organization needs to own every component of the cell therapy pathway. Blood centers, community hospitals, academic institutions, manufacturers, and specialized laboratories each contribute distinct expertise. Connected through shared quality systems, regulatory oversight, and reliable chain-of-identity processes, they become one system capable of expanding access while preserving the rigor advanced cell therapies demand.
CAR T began within academic medical centers. Where it goes next will be determined by how effectively healthcare systems work together beyond their walls.